Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-γ and expanding CD4 + Foxp3 + T cells in concordant heart transplantation

Laboratory Investigation

Volumn 96, Issue 8, 2016, Pages 820-829

  Dai, Chen ^a,b   Lu, Fang Na ^c   Jin, Ning ^c   Yang, Bo ^a,b   Gao, Chang ^c   Zhao, Bin ^c   Fu, Jia Zhao ^c   Hong, Shi Fu ^c   Liang, Han Ting ^c   Chen, Li Hong ^c   Chen, Zhi Shui ^a,b   Chen, Jie ^c   Qi, Zhong Quan ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING HOSPITAL   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 33; INTERLEUKIN 4; LEFLUNOMIDE; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 33; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, RAT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMORAL IMMUNITY; MIXED LYMPHOCYTE REACTION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; DRUG EFFECTS; DRUG POTENTIATION; IMMUNOLOGY; LEWIS RAT; METABOLISM; SPLEEN; XENOGRAFT;

ANIMALS; B-LYMPHOCYTES; CYTOKINES; DRUG SYNERGISM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROGRAFTS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-33; ISOXAZOLES; MICE; MICE, INBRED C57BL; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84980000694     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2016.54     Document Type: Article

References (29)

1. Yan Y, Verbeken E, Yu L, et al. Effects of a short course of leflunomide on T-independent B-lymphocyte xenoreactivity and on susceptibility of xenografts to acute or chronic rejection. Transplantation 2005;79: 135-141.
2. Cheng PP, Liu XC, Ma PF, et al. iPSC-MSCs combined with low-dose rapamycin induced islet allograft tolerance through suppressing Th1 and enhancing regulatory T-cell differentiation. Stem Cells Dev 2015;24:1793-1804.
3. Biglarnia AR, Emanuelsson C, Quach M, et al. The free radical scavenger S-PBN significantly prolongs DSG-mediated graft survival in experimental xenotransplantation. Xenotransplantation 2012;19:166-176.
4. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011;187:4598-4610.
5. Liu Q, Turnquist HR. Implications for Interleukin-33 in solid organ transplantation. Cytokine 2013;62:183-194.
6. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014;513: 564-568.
7. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165: 5962-5969.
8. Hassikou H, El Haouri M, Tabache F, et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine 2008;75:597-599.
9. Sobhani K, Garrett DA, Liu DP, et al. A rapid and simple highperformance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. Am J Clin Pathol 2010;133:454-457.
10. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-2555.
11. Eyre DW, Babakhani F, Griffiths D, et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014;209:1446-1451.
12. Yin H, Li XY, Jin XB, et al. IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation 2010;89:1189-1197.
13. Laumonier T, Mohacsi PJ, Matozan KM, et al. Endothelial cell protection by dextran sulfate: a novel strategy to prevent acute vascular rejection in xenotransplantation. Am J Transplant 2004;4:181-187.
14. Wang Q, Liu Y, Li XK. Simplified technique for heterotopic vascularized cervical heart transplantation in mice. Microsurgery 2005;25:76-79.
15. Lin Y, Dai H, Su J, et al. Arsenic trioxide is a novel agent for combination therapy to prolong heart allograft survival in allo-primed T cells transferred mice. Transpl Immunol 2011;25:194-201.
16. Dujovny N, Varghese A, Shen J, et al. Acute xenograft rejection mediated by antibodies produced independently of TH1/TH2 cytokine profiles. Am J Transplant 2002; 526-534.
17. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-490.
18. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012;33:389-396.
19. Sayegh MH1 AE, Hancock WW, Russell ME, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 1869-1874.
20. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23-33.
21. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol 2007;17:178-186.
22. Farahani R, Sherkat R, Hakemi MG, et al. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res 2014;3:127.
23. Kupiec-Weglinski JW1 WB, Papp I, Schmidbauer G, et al. CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokine. J Immunol 1993;151:5053-5061.
24. He X, Wu W, Lu Y, et al. Effect of interleukin-33 on Th1/Th2 cytokine ratio in peripheral lymphocytes in asthmatic mice. Chin Med J (Engl) 2014;127:1517-1522.
25. Brunner SM, Schiechl G, Falk W, et al. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 2011;24: 1027-1039.
26. Li B, Tian L, Diao Y, et al. Exogenous IL-10 induces corneal transplantation immune tolerance by a mechanism associated with the altered Th1/Th2 cytokine ratio and the increased expression of TGF-?. Mol Med Rep 2014; 2245-2250.
27. Hall BM1 PN, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990;171:141-157.
28. Chong AS1 ML, Yin D, Blinder L, et al. Tolerance of T-independent xeno-antibody responses in the hamster-to-rat xenotransplantation model is species-restricted but not tissue-specific. Xenotransplantation 2000;7:1.
29. Bersztel A, Lorant T, Bjorkland A, et al. Antibody responses to xenogenic antigens-a study in the mouse-to-rat system. Tissue Antigens 2006;68:483-488.